Resumen de: US2025154231A1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: US2025152566A1
The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.
Resumen de: US2025152613A1
Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).
Resumen de: AU2023366039A1
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
Resumen de: US2025154230A1
The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.
Resumen de: US2025152618A1
The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.
Resumen de: US2025155438A1
Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.
Resumen de: US2025155436A1
Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.
Resumen de: WO2025101653A1
Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.
Resumen de: US2025154204A1
The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.
Resumen de: EP4553080A1
The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.
Resumen de: WO2025100882A1
The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.
Resumen de: EP4553084A2
The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.
Resumen de: KR20250064724A
본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.
Resumen de: KR20250064725A
본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.
Resumen de: AU2023375471A1
Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.
Resumen de: US2025144087A1
The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.
Resumen de: US2025145667A1
The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.
Resumen de: US2025144163A1
A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.
Resumen de: US2025144199A1
The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.
Resumen de: US2025144201A1
A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.
Resumen de: US2025144119A1
Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.
Resumen de: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Resumen de: US2025145690A1
Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.
Nº publicación: US2025145691A1 08/05/2025
Solicitante:
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Resumen de: US2025145691A1
Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.